- Company positioned for key MM-120 Phase 2b data readout in GAD and Phase 2a data readout in ADHD in late 2023
- Company to initiate first clinical trial of MM-402 in 2023
Read more at newswire.caProvided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.